United States - English - NLM (National Library of Medicine)

proficient rx lp - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: – due to streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . – due to escherichia coli, proteus mirabilis , or enterococcus faecalis . – due to streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . – due to streptococcus s

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - adults and pediatric patients - upper respiratory tract infections of the ear, nose, and throat:   amoxicillin capsules   are indicated in the treatment of infections due to susceptible (only β- lactamase–negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . - infections of the genitourinary tract: amoxicillin capsules   are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . - infections of the skin and skin structure:  amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, usp and other antibacterial drugs, amoxicillin capsules, usp should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.  amoxicillin capsules, usp are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: due to streptococcus species (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . due to escherichia coli, proteus mirabilis , or enterococcus faecalis . due to streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradicati

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - adults and pediatric patients - upper respiratory tract infections of the ear, nose, and throat:   amoxicillin capsules   are indicated in the treatment of infections due to susceptible (only β- lactamase–negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . - infections of the genitourinary tract: amoxicillin capsules   are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . - infections of the skin and skin structure:  amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or

United States - English - NLM (National Library of Medicine)

morton grove pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 250 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension (amoxicillin/clavulanate potassium) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium for oral suspension is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta-lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanic acid (unii: 23521w1s24) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 400 mg in 5 ml -        to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium powder for oral suspension, usp (amoxicillin/clavulanate potassium) and other antibacterial drugs, amoxicillin and clavulanate potassium powder for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.       amoxicillin and clavulanate potassium powder for oral suspension, usp is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: - caused by beta-lactamase-producing isolates of

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), amoxicillin sodium (unii: 544y3d6myh) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 562.5 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium extended release tablets and other antibacterial drugs, amoxicillin and clavulanate potassium extended release tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium extended release tablets is indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase–producing pathogens (i.e., h. influenzae , m. catarrhalis , h. parainfluenzae , k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penic

United States - English - NLM (National Library of Medicine)

american antibiotics,inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin 250 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin